Clear, engaging, and practical updates on clinical psychiatry.

Subscribe for free on Apple Podcasts, Android, or Stitcher. Let us know what you think and suggest topics by taking the Podcast Survey.

Previous Post
Episode
Next Post
Episode

The Stats on a Dayvigo: A New Hypnotic [60 Sec Psych]

Podcast, Volume , Number ,
https://www.thecarlatreport.com///

Print Friendly, PDF & Email

Lemborexant/Dayvigo is the second in sleep med to join the orexin receptor antagonist family. It’s now on the pharmacy shelves, where it sits beside Suvorexant/Bellsomra, released in 2015. Landry I, Nakai K, Ferry J, et al. Pharmacokinetics, pharmacodynamics, and safety of the dual orexin receptor antagonist lemborexant: Findings from single-dose and multiple-ascending-dose phase 1 studies in healthy adults. Clin Pharmacol Drug Dev. 2020;10.1002/cpdd.817. [Link]

Published Today: 6/27/20

Duration: 1 minute, 49 seconds

Transcript:

Lemborexant/Dayvigo is the second in sleep med to join the orexin receptor antagonist family. It’s now on the pharmacy shelves, where it sits beside Suvorexant/Bellsomra, released in 2015. Today, we review its pharmacokinetics from a new industry-sponsored meta-analysis of 3 RCTs by Ishani Landry:

Lemborexant reaches its peak in 1-3 hours. Tell patients to take it right before going to bed.

Its half life is 17-19 hours, 30% of the drug is still in the bloodstream the next morning, but this didn’t seem to cause any next-day functional effects. Patients should allow at least 7 hours of sleep when they take lemborexant. One advantage of the orexin class is that they are better studied ─ and have better safety metrics ─ in the elderly than the z-hypnotics.

Start lemborexant at 5 mg/night and titrated as needed to a max of 10 mg/night. Watch out for drug interactions with CYP3A inhibitors and inducers. Strong CYP3A inhibitors like nefazodone and HIV meds can increase it 4-fold, while moderate ones like the calcium channel blockers increase it about 1.5 fold.

The analysis included a Japanese study, but race did not seem to effect lemborexant‘s pharmacokinetics

Got Feedback? Take the podcast survey.


Comments

    Leave A Comment

    Your email address will not be published. Required fields are marked *